Moomoo reports USD 15.75 target for Iovance Biotherapeutics stock

Published on 10/24/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moomoo counted 8 analyst ratings on October 23, 2026, all marked Buy. Iovance Biotherapeutics stock costs EUR 12.57 on October 24, 2026.

Analyst target and price frame

Moomoo reported an average 12-month target of USD 15.75 from eight analyst ratings on October 23, 2026.
Iovance raised its full-year 2026 revenue outlook to USD 410.00 million-USD 420.00 million on September 29, 2026.
Iovance Biotherapeutics stock costs EUR 12.57 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
The Nasdaq-listed stock has a USD 1.76-USD 15.37 52-week range.

IOVA, US4622601007, Illustration mit AI erstellt.

Moomoo reported on October 23, 2026 that eight analysts rated Iovance Biotherapeutics Buy and put the average 12-month target at USD 15.75. Iovance Biotherapeutics stock was trading at EUR 12.57 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Analyst target stays above Nasdaq price

The USD 15.75 average target is above the Nasdaq last price of USD 14.09 on October 23, 2026 at 4:00 p.m. ET. The comparison is a market reference rather than a forecast by Iovance, and the eight-rating sample is smaller than the 13-firm consensus reported earlier in October.

Moomoo listed all eight ratings as Buy and showed a maximum target of USD 20.00 and a minimum target of USD 8.00 on October 23, 2026.

Revenue outlook supports valuation debate

The Financial Times reported that Iovance raised its full-year 2026 revenue guidance on September 29, 2026 to USD 410.00 million-USD 420.00 million from USD 350.00 million-USD 370.00 million. The midpoint increased by USD 55.00 million, from USD 360.00 million to USD 415.00 million.

The latest reported quarter supplied the operating baseline. MarketBeat said second-quarter 2026 revenue reached USD 99.31 million, up 65.70 percent year over year, while adjusted loss per share was USD 0.11 against a USD 0.13 consensus loss.

Price range remains wide

Moomoo listed a 52-week range of USD 1.76 to USD 15.37, placing the Nasdaq stock near the upper end of its annual span. The same October 23, 2026 quote showed a market capitalization of USD 6.4 billion and volume of 7.75 million shares.

Iovance develops tumor-infiltrating lymphocyte cell therapies, with Amtagvi as its approved treatment for certain advanced melanoma patients. Its investor materials state that the therapy is available at nearly 100 authorized treatment centers, while the company continues to expand its clinical platform.

Upcoming results set the next date

Iovance expects to report third-quarter 2026 financial results in early November 2026, according to the company release carried by StockTitan. The report will test whether the second-quarter revenue pace and the raised full-year range remain consistent with commercial execution.

The Nasdaq last price was USD 14.09 on October 23, 2026 at 4:00 p.m. ET, while the euro quotation from Lang & Schwarz stood at EUR 12.57 on October 24, 2026 at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Iovance Biotherapeutics stock.